$KYTH News
Last published 7mo ago
- 7mo agoLBPHARNAKYTHSensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual ReportBusiness WireGJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month
- 1y agoLBPHARNAKYTHAGN+1Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent DirectorBusiness WireRegulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today
- 11y agoKYTHFinkelstein Thompson LLP Investigates Potentially Unfair Buyout of KYTHERA Biopharmaceuticals, Inc.Business WireWASHINGTON--(BUSINESS WIRE)--Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of KYTHERA Biopharmaceuticals, Inc. (“Kythera” or the “Company”) (NasdaqGS: KYTH), concerning the Company’s proposed acquisition by Allergan plc. Under the terms of the proposal, KYTHERA shareholders will receive $75.00 in cash for each share of KYTHERA common stock they own. At least ...
- 11y agoKYTHLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of KYTHERA Biopharmaceuticals, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (“KYTHERA” or the “Company”) (NASDAQ:KYTH) concerning the proposed acquisition of the Company by Allergan plc (“Allergan”). Pursuant to the terms of the definitive merger agreement, KYTHERA stockholders will have the right to receive $75.00 in a combin ...
- 13y agoKYTHKYTHERA Biopharmaceuticals, Inc. Presents Positive Magnetic Resonance Imaging (MRI) Results from Phase IIb Study of ATX-101 in the Reduction of Submental Fat or “Double Chin”Business WireNEW YORK--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery (ASAPS) ...
- 13y agoKYTHKYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Phase IIIb Study of ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC)Business WireMONTE CARLO, Monaco--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the “Innovations and Renewals” session of the 11th Anti-Aging Medicine World Congress (AMWC), April 4-6, Monte Carlo, Monaco. The study, presented by investigator Susan Weinkle, MD, FAAD, ev ...
- 13y agoKYTHKYTHERA Biopharmaceuticals Announces 2012 Operating ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its quarter and year ended December 31, 2012.
- 13y agoKYTHMedical Aesthetics Veteran Frederick Beddingfield, III, MD, PhD Appointed New Chief Medical Officer of KYTHERA BiopharmaceuticalsBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH), a biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the appointment of Frederick Beddingfield, III, MD, PhD as Chief Medical Officer. Dr. Beddingfield is a board-certified dermatologist who brings exceptional pharmaceutical and medical d ...
- 13y agoKYTHKYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Study of ATX-101 in the Reduction of Unwanted Submental Fat (SMF) or “Double Chin”Business WireMIAMI BEACH, Fla.--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced positive interim results from a Phase IIIb, multi-center, open-label study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat (SMF), commonly known as double chin. The results, presented at the Late Breaking ...
- 13y agoKYTHKYTHERA Biopharmaceuticals, Inc. to Present New Data at 2013 American Academy of Dermatology (AAD) Annual Meeting Demonstrating Results for ATX-101 in the Reduction of Submental Fat (SMF) or “Double Chin”Business WireMIAMI BEACH, Fla.--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla. The abstracts, including one to be presented at the Late Breaking Research Symposium on March 2, evaluate the safety, efficacy and pharmacokinetics of ATX-101, an investigational in ...
- 13y agoKYTHKYTHERA Biopharmaceuticals to Present at Cowen and Company 33rd Annual Health Care ConferenceBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, President and Chief Executive Officer, will present at the Cowen and Company 33rd Annual Health Care Conference in Boston.
- 13y agoKYTHKYTHERA Biopharmaceuticals to Present at 2013 RBC Global Healthcare ConferenceBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, President and Chief Executive Officer, will present at the 2013 RBC Global Healthcare Conference in New York.
- 13y agoKYTHKYTHERA Biopharmaceuticals to Present at Leerink Swann Global Healthcare ConferenceBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, President and Chief Executive Officer, will present at the Leerink Swann Global Healthcare Conference 2013 in New York.
- 13y agoKYTHKYTHERA Biopharmaceuticals Added to Russell 3000, 2000, Global and Microcap IndexesBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the company has been added to each of the broad-market Russell 3000® Index, the Russell 2000® Index, the Russell Microcap® Index and the Russell Global® Index as part of Russell's quarterly IPO additions effective as of the close of trading on December 21, 2012.
- 13y agoKYTHKYTHERA Biopharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare ConferenceBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.
- 13y agoKYTHKYTHERA Biopharmaceuticals Announces Limited Lock-up Release of Shares for Charitable DonationBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today that J.P. Morgan Securities LLC and Goldman, Sachs & Co., the lead book-running managers in the Company’s recent public sale of 5,060,000 shares of common stock, are releasing a lock-up restriction with respect to 7,563 shares of the Company’s common stock held by Keith Leonard, President and Chief Execut ...
- 13y agoKYTHKYTHERA Biopharmaceuticals Announces Results from Open-Label Study for ATX-101Business WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced interim study results from Study ATX-101-11-26, a multicenter, open-label, long-term study to evaluate the safety of ATX-101, a facial injectable drug for the reduction of submental fat (SMF), which commonly presents as an unwanted double chin.
- 14y agoKYTHKYTHERA Biopharmaceuticals Announces Third Quarter 2012 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the three and nine months ended September 30, 2012, and provided an update on recent accomplishments.
- 14y agoKYTHKYTHERA Biopharmaceuticals to Present at Lazard Capital Markets 9th Annual Healthcare ConferenceBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the Lazard Capital Markets 9th Annual Healthcare Conference in New York City.
- 14y agoKYTHKYTHERA Biopharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment OptionBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the closing of its initial public offering of 5,060,000 shares of its common stock at an initial public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 660,000 additional shares of common stock. KYTHERA Biopharmaceuticals’ commo ...
- 14y agoKYTHKYTHERA Biopharmaceuticals Announces Pricing of Initial Public OfferingBusiness WireLOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) today announced the pricing of its initial public offering of 4,400,000 shares of its common stock at a price to the public of $16.00 per share. The shares of KYTHERA's common stock will trade on the NASDAQ Global Select Market under the symbol "KYTH." All of the shares of common stock are being offered by KYTHERA. In addit ...